Poly(l-lysine)/DNAct complexes associate with blood cells in vivo
| Time . | pLL20/DNAct . | pLL211/DNAct . | DNAct . |
|---|---|---|---|
| 1 min | 91.4 ± 5.7 | 92.0 ± 5.3 | 4.6 ± 0.1 |
| (83.4 ± 3.7) | (94.0 ± 2.9) | (75.0 ± 1.2) | |
| 10 min | 85.6 ± 7.2 | 95.5 ± 1.0 | 3.5 ± 0.1 |
| (17.4 ± 5.5) | (66.0 ± 5.3) | (5.0 ± 0.9) |
| Time . | pLL20/DNAct . | pLL211/DNAct . | DNAct . |
|---|---|---|---|
| 1 min | 91.4 ± 5.7 | 92.0 ± 5.3 | 4.6 ± 0.1 |
| (83.4 ± 3.7) | (94.0 ± 2.9) | (75.0 ± 1.2) | |
| 10 min | 85.6 ± 7.2 | 95.5 ± 1.0 | 3.5 ± 0.1 |
| (17.4 ± 5.5) | (66.0 ± 5.3) | (5.0 ± 0.9) |
pLL20/DNAct, pLL211/DNAct complexes or DNActwere administered intravenously to female Balb/c mice (0.1 mL of 10 μg/mL DNA). The mice were killed after 1 and 10 minutes, and the blood was sampled and immediately spun at 5000 rpm at 4°C to pellet the blood cells. Pellet and supernatant were assayed for32P-levels, and the results show the percentage of radioactivity present in the blood associating with the cell pellet. Numbers in brackets indicate the percentage of the original32P dose remaining in the blood at the time of sampling. Results show the mean ± SD of 3 independent experiments. Similar results were obtained using pLL/DNAcp complexes (data not shown).
For abbreviations, see Table 1.